Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lin Shen

Showing results (1501-1510 of 1,553) with videos related to

Pageof 156
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2021
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)Feng-Hua Wang, Xiao-Li Wei, Jifeng Feng, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2025
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)Jianming Xu, Lin Shen, Jie Li, et al.
BMC Cancer|October 4, 2025
Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancersYing Liu, Wei He, Qi Wu, et al.
American Journal of Hematology|June 23, 2026
A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and PrognosisJing Li, Chenqi Yu, Jinghua Wang, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Zhiwei Zhou, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2024
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trialPanpan Zhang, Si Shi, Jianming Xu, et al.
Science (New York, N.Y.)|June 1, 2023
Rhythmic cilia changes support SCN neuron coherence in circadian clockHai-Qing Tu, Sen Li, Yu-Ling Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2025
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid TumorsGeoffrey Ku, Lin Shen, Farshid Dayyani, et al.
Science Advances|March 6, 2020
Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapyZiyu Li, Xiangyu Gao, Xinxin Peng, et al.
JAMA Network Open|August 16, 2021
Prevalence of Osteoporosis and Fracture in China: The China Osteoporosis Prevalence StudyLinhong Wang, Wei Yu, Xiangjun Yin, et al.
Pageof 156

Showing results (1501-1510 of 1,553) with videos related to

Sort By:
Pageof 156
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2021
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)Feng-Hua Wang, Xiao-Li Wei, Jifeng Feng, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2025
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)Jianming Xu, Lin Shen, Jie Li, et al.
BMC Cancer|October 4, 2025
Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancersYing Liu, Wei He, Qi Wu, et al.
American Journal of Hematology|June 23, 2026
A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and PrognosisJing Li, Chenqi Yu, Jinghua Wang, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Zhiwei Zhou, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2024
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trialPanpan Zhang, Si Shi, Jianming Xu, et al.
Science (New York, N.Y.)|June 1, 2023
Rhythmic cilia changes support SCN neuron coherence in circadian clockHai-Qing Tu, Sen Li, Yu-Ling Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2025
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid TumorsGeoffrey Ku, Lin Shen, Farshid Dayyani, et al.
Science Advances|March 6, 2020
Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapyZiyu Li, Xiangyu Gao, Xinxin Peng, et al.
JAMA Network Open|August 16, 2021
Prevalence of Osteoporosis and Fracture in China: The China Osteoporosis Prevalence StudyLinhong Wang, Wei Yu, Xiangjun Yin, et al.
Pageof 156